After completing his internal medicine residency and fellowship and board certification in Medical Oncology he worked as an Attending Physician for 8 years in the Urgent Care Center at Memorial-Sloan Cancer Center. In 2006 Chris moved to the pharmaceutical industry working at Sanofi as a Global Safety Officer in Oncology based in Bridgewater, New Jersey. There, he worked on numerous development programs, partnerships, and submissions, including the approval of the antiangiogenic aflibercept.
In 2011 he moved to Boston when Sanofi acquired Genzyme and remained in Oncology. In late 2013 he moved to the position of Global Pharmacovigilance Head for the Sanofi-Genzyme Global Business Unit where he was responsible for the pharmacovigilance oversight for the therapeutic areas of Rare Disease, Multiple Sclerosis, Oncology and Immunology/Inflammation. He is currently the Pharmacovigilance Head at Moderna Therapeutics in Cambridge Massachusetts.